This company look to have a solid business moving forward and now adding the MM business focusing on the very lucrative North American market.
Too many positives to ignore here, and looks undervalued on current business alone....
- Revenues for 12 months to 31 December 2016 $4.2 million.
- Advisory fees earned $2.74 million – 218.6% increase on previous year.
- Net Profit After Tax $1.858 million.
- Net Tangible Asset value $11.006 million – 105.14% increase on previous year.
- Net Tangible Asset backing per share 3.67c per share.
- Investment portfolio Fair Market Value $14.807m.
Talking to more than one Medical Cannibas company currently. News won't be far away!
"CIL is a specialist cannabis investment company that will seek to pursue high quality, value accretive investment opportunities for the Company in the rapidly emerging global medicinal cannabis sector.
Chapmans advises that
CIL is currently in advanced stage negotiations with a number of substantial high quality medicinal cannabis investment opportunities that meet its investment parameters, and will inform the market of any material developments or outcomes as they progress."
"These
will include the veterinary science and animal treatment markets, which utilise high value processed and extract medicinal cannabis products, and value added services.
CIL will also seek to
pursue global licensing and distribution opportunities for its investments, to help ensure maximum market penetration and return on investment. It will initially
focus on North America, which is acknowledged as the world’s largest medicinal cannabis market.
"The Company is pleased to advise that it
has appointed leading medicinal cannabis sector expert, Mr Cameron McDonald-Stuart to the board of CIL. He will play a key role in identifying and assessing potential investment opportunities for CIL, and also in implementing and overseeing the business model of investments made by CIL."
Management values the company at 3.6c per share with out the Medical Cannibas business, so can only see this rerating massively on any Quality Medical Cannibas deal in North America in coming weeks.
